Tanezumab
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bone Metastasis
Conditions
Bone Metastasis, Cancer Pain
Trial Timeline
Oct 28, 2015 → Jun 25, 2021
NCT ID
NCT02609828About Tanezumab
Tanezumab is a phase 3 stage product being developed by Eli Lilly for Bone Metastasis. The current trial status is completed. This product is registered under clinical trial identifier NCT02609828. Target conditions include Bone Metastasis, Cancer Pain.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02609828 | Phase 3 | Completed |
Competing Products
20 competing products in Bone Metastasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Denosumab + Zoledronic Acid | Daiichi Sankyo | Phase 3 | 77 |
| Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| Tacrolimus | Astellas Pharma | Phase 2 | 52 |
| Tacrolimus | Astellas Pharma | Phase 2 | 52 |
| Merestinib | Eli Lilly | Phase 1 | 33 |
| FORTEO + Placebo | Eli Lilly | Phase 1 | 33 |
| Arzoxifene + Placebo | Eli Lilly | Phase 3 | 77 |
| Anastrozole + Tamoxifen | AstraZeneca | Phase 3 | 77 |
| zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplements | Novartis | Phase 3 | 77 |
| Zoledronic acid | Novartis | Phase 3 | 77 |
| Zoledronic acid + Letrozole | Novartis | Phase 3 | 77 |
| Zoledronic acid | Novartis | Phase 3 | 77 |
| Nilotinib | Novartis | Phase 1 | 33 |
| Reclast (ZOL446, zoledronic acid) | Novartis | Approved | 85 |
| Zoledronic acid | Novartis | Phase 3 | 77 |
| Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic Acid | Novartis | Phase 3 | 77 |
| zoledronic acid | Novartis | Phase 1 | 33 |
| Ruxolitinib continuous therapy | Novartis | Phase 2 | 52 |
| zoledronic acid | Novartis | Approved | 85 |